{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:53:20Z","timestamp":1769165600738,"version":"3.49.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CEN Case Rep"],"DOI":"10.1007\/s13730-022-00737-8","type":"journal-article","created":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T17:04:15Z","timestamp":1664557455000},"page":"152-158","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A case of crescentic glomerulonephritis induced by afatinib for lung adenocarcinoma"],"prefix":"10.1007","volume":"12","author":[{"given":"Daisuke","family":"Morita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2082-9871","authenticated-orcid":false,"given":"Kenji","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobumitsu","family":"Ikeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Nishida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiyasu","family":"Igata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsubasa","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maho","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuhiko","family":"Yasuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriko","family":"Uesugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Oda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kosuke","family":"Masutani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"737_CR1","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1126\/science.1099314","volume":"304","author":"JG Paez","year":"2004","unstructured":"Paez JG, J\u00e4nne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497\u2013500.","journal-title":"Science"},{"key":"737_CR2","doi-asserted-by":"publisher","first-page":"5589","DOI":"10.1200\/JCO.2008.16.7254","volume":"26","author":"T Takano","year":"2008","unstructured":"Takano T, Fukui T, Ohe Y, et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. J Clin Oncol. 2008;26:5589\u201395.","journal-title":"J Clin Oncol"},{"key":"737_CR3","doi-asserted-by":"publisher","first-page":"iv192","DOI":"10.1093\/annonc\/mdy275","volume":"29","author":"D Planchard","year":"2018","unstructured":"Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO clinical practice guidelines for diagnosis treatment and follow-up. Ann Oncol. 2018;29:iv192\u2013237.","journal-title":"Ann Oncol"},{"key":"737_CR4","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/annonc\/mdy554","volume":"30","author":"YL Wu","year":"2019","unstructured":"Wu YL, Planchard D, Lu S, et al. Pan-Asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO-ESMO initiative endorsed by JSMO, KSMO, MOS SSO and TOS. Ann Oncol. 2019;30:171\u2013210.","journal-title":"Ann Oncol"},{"key":"737_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/S1470-2045(16)30033-X","volume":"17","author":"K Park","year":"2016","unstructured":"Park K, Tan EH, O\u2019Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17:577\u201389.","journal-title":"Lancet Oncol"},{"key":"737_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:213\u201322.","journal-title":"Lancet Oncol"},{"key":"737_CR7","doi-asserted-by":"publisher","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31:3327\u201334.","journal-title":"J Clin Oncol"},{"key":"737_CR8","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S1470-2045(15)00006-6","volume":"16","author":"JC Soria","year":"2015","unstructured":"Soria JC, Felip E, Cobo M, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2015;16:897\u2013907.","journal-title":"Lancet Oncol"},{"key":"737_CR9","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1586\/era.13.31","volume":"13","author":"JC Yang","year":"2013","unstructured":"Yang JC, Reguart N, Barinoff J, et al. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013;13:729\u201336.","journal-title":"Expert Rev Anticancer Ther"},{"key":"737_CR10","unstructured":"Pharmaceutical interview form of Giotrif Tablets. Nippon Boehringer Ingelheim Co. L, editor. 2020. https:\/\/www.bij-kusuri.jp\/products\/attach\/pdf\/gio_t20_if.pdf"},{"key":"737_CR11","unstructured":"Guidelines for the treatment of rapidly progressive glomerulonephritis, second version. Nihon Jinzo Gakkai Shi. 2011; 53:509\u201355."},{"key":"737_CR12","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/ki.1996.94","volume":"49","author":"L Gesualdo","year":"1996","unstructured":"Gesualdo L, Di Paolo S, Calabr\u00f3 A, et al. Expression of epidermal growth factor and its receptor in normal and diseased human kidney: an immunohistochemical and in situ hybridization study. Kidney Int. 1996;49:656\u201365.","journal-title":"Kidney Int"},{"key":"737_CR13","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1038\/nm.2491","volume":"17","author":"G Boll\u00e9e","year":"2011","unstructured":"Boll\u00e9e G, Flamant M, Schordan S, et al. Epidermal growth factor receptor promotes glomerular injury and renal failure in rapidly progressive crescentic glomerulonephritis. Nat Med. 2011;17:1242\u201350.","journal-title":"Nat Med"},{"key":"737_CR14","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.vph.2009.06.008","volume":"51","author":"IF Benter","year":"2009","unstructured":"Benter IF, Benboubetra M, Hollins AJ, et al. Early inhibition of EGFR signaling prevents diabetes-induced up-regulation of multiple gene pathways in the mesenteric vasculature. Vasc Pharmacol. 2009;51:236\u201345.","journal-title":"Vasc Pharmacol"},{"key":"737_CR15","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1096\/fj.03-0702fje","volume":"18","author":"H Fran\u00e7ois","year":"2004","unstructured":"Fran\u00e7ois H, Placier S, Flamant M, et al. Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition. Faseb J. 2004;18:926\u20138.","journal-title":"Faseb J"},{"key":"737_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1159\/000045962","volume":"88","author":"MK Hise","year":"2001","unstructured":"Hise MK, Salmanullah M, Liu L, et al. Control of the epidermal growth factor receptor and its ligands during renal injury. Nephron. 2001;88:71\u20139.","journal-title":"Nephron"},{"key":"737_CR17","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1440-1797.2009.01100.x","volume":"14","author":"Y Gao","year":"2009","unstructured":"Gao Y, Zhao MH. Review article: drug-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Nephrology. 2009;14:33\u201341.","journal-title":"Nephrology"},{"key":"737_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s13730-021-00632-8","author":"R Oki","year":"2021","unstructured":"Oki R, Hirakawa Y, Oda Y, et al. Renal-limited ANCA-associated vasculitis during erlotinib treatment for lung carcinoma. CEN Case Rep. 2021. https:\/\/doi.org\/10.1007\/s13730-021-00632-8.","journal-title":"CEN Case Rep"},{"key":"737_CR19","first-page":"512","volume":"2","author":"N Kurita","year":"2009","unstructured":"Kurita N, Mise N, Fujii A, et al. Crescentic glomerulonephritis in a patient with advanced lung cancer during erlotinib therapy. NDT Plus. 2009;2:512\u20133.","journal-title":"NDT Plus"},{"key":"737_CR20","first-page":"764","volume":"9","author":"L Nakopoulou","year":"1994","unstructured":"Nakopoulou L, Stefanaki K, Boletis J, et al. Immunohistochemical study of epidermal growth factor receptor (EGFR) in various types of renal injury. Nephrol Dial Transpl. 1994;9:764\u20139.","journal-title":"Nephrol Dial Transpl"},{"key":"737_CR21","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1007\/s00228-013-1532-6","volume":"69","author":"E Faye","year":"2013","unstructured":"Faye E, Bondon-Guitton E, Olivier-Abbal P, et al. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol. 2013;69:1819\u201326.","journal-title":"Eur J Clin Pharmacol"},{"key":"737_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13256-018-1877-7","volume":"13","author":"H Kamo","year":"2019","unstructured":"Kamo H, Shinozaki E, Sugase T, et al. Leukocytoclastic vasculitis with purpura and renal failure induced by the anti-epidermal growth factor receptor antibody panitumumab: a case report. J Med Case Rep. 2019;13:13.","journal-title":"J Med Case Rep"},{"key":"737_CR23","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/hed.21481","volume":"34","author":"K Yang","year":"2012","unstructured":"Yang K, Zhang T, Chen J, et al. Immune thrombocytopenia as a paraneoplastic syndrome in patients with nasopharyngeal cancer. Head Neck. 2012;34:127\u201330.","journal-title":"Head Neck"},{"key":"737_CR24","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1111\/j.1346-8138.2010.00896.x","volume":"37","author":"H Uchimiya","year":"2010","unstructured":"Uchimiya H, Higashi Y, Kawai K, et al. Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib. J Dermatol. 2010;37:562\u20134.","journal-title":"J Dermatol"},{"key":"737_CR25","first-page":"1128","volume":"17","author":"GL Fekete","year":"2019","unstructured":"Fekete GL, Fekete L. Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: a case report and review of the literature. Exp Ther Med. 2019;17:1128\u201331.","journal-title":"Exp Ther Med"}],"container-title":["CEN Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-022-00737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13730-022-00737-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13730-022-00737-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T07:09:52Z","timestamp":1682924992000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13730-022-00737-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":25,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["737"],"URL":"https:\/\/doi.org\/10.1007\/s13730-022-00737-8","relation":{},"ISSN":["2192-4449"],"issn-type":[{"value":"2192-4449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have declared that no conflict of interests exists.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}